A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from erspc rotterdam

European Urology

Volumn 63, Issue 4, 2013, Pages 627-633

  Roobol, Monique J ^a   Zhu, Xiaoye ^a   Schröder, Fritz H ^a   Van Leenders, Geert J L H ^a   Van Schaik, Ron H ^a   Bangma, Chris H ^a   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Early detection; Prostate biopsy; Prostate cancer; Prostate specific antigen; Risk calculator; Risk based screening; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; FOLLOW UP; GLEASON SCORE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY;

AGED; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; RISK ASSESSMENT;

EID: 84874530270     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.07.029     Document Type: Article

References (31)

1. F.K.-H. Chun, P.I. Karakiewicz, and A. Briganti Prostate cancer nomograms: an update Eur Urol 50 2006 914 926 discussion 926
2. F.K. Chun, P.I. Karakiewicz, H. Huland, and M. Graefen Role of nomograms for prostate cancer in 2007 World J Urol 25 2007 131 142
3. R. Kranse, M. Roobol, and F.H. Schröder A graphical device to represent the outcomes of a logistic regression analysis Prostate 68 2008 1674 1680
4. E.W. Steyerberg, M.J. Roobol, M.W. Kattan, T.H. van der Kwast, H.J. de Koning, and F.H. Schroder Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram J Urol 177 2007 107 112 discussion 112
5. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
6. F. Schröder, and M.W. Kattan The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review Eur Urol 54 2008 274 290
7. S. Loeb, H.B. Carter, W.J. Catalona, J.W. Moul, and F.H. Schroder Baseline prostate-specific antigen testing at a young age Eur Urol 61 2012 1 7
8. M.J. Roobol, F.H. Schröder, and E.D. Crawford A framework for the identification of men at increased risk for prostate cancer J Urol 182 2009 2112 2120
9. X. Zhu, P.C. Albertsen, G.L. Andriole, M.J. Roobol, F.H. Schröder, and A.J. Vickers Risk-based prostate cancer screening Eur Urol 61 2012 652 661
10. M.J. Roobol, W.J. Kirkels, and F.H. Schroder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands) BJU Int 92 Suppl 2 2003 48 54
11. R. Raaijmakers, B.G. Blijenberg, and J.A. Finlay Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness J Urol 171 2004 2245 2249
12. M.J. Roobol, R. Kranse, H.J. de Koning, and F.H. Schroder Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam) Urology 63 2004 309 313 discussion 313-5
13. M.J. Roobol, H.A. van Vugt, and S. Loeb Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators Eur Urol 61 2012 577 583
14. S. Loeb, M. Han, K.A. Roehl, J.A. Antenor, and W.J. Catalona Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography J Urol 173 2005 63 65
15. E.W. Steyerberg, A.J. Vickers, and N.R. Cook Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 21 2010 128 138
16. C. Stephan, H. Cammann, and H.A. Meyer An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics BJU Int 102 2008 799 805
17. H.A. van Vugt, M.J. Roobol, and L.D. Venderbos Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator Eur J Cancer 46 2010 669 677
18. H.A. van Vugt, M.J. Roobol, and M. Busstra Compliance with biopsy recommendations of a prostate cancer risk calculator BJU Int 109 2012 1480 1488
19. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
20. F.H. Schroder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
21. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
22. E.W. Steyerberg, F.E. Harrell Jr., G.J. Borsboom, M.J. Eijkemans, Y. Vergouwe, and J.D. Habbema Internal validation of predictive models: efficiency of some procedures for logistic regression analysis J Clin Epidemiol 54 2001 774 781
23. F.H. Schröder, R.C.N. van den Bergh, and T. Wolters Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies Eur Urol 57 2010 256 266
24. H. Miyake, T. Kurahashi, A. Takenaka, I. Hara, and M. Fujisawa Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores Urol Int 79 2007 302 306
25. I.F. San Francisco, W.C. DeWolf, S. Rosen, M. Upton, and A.F. Olumi Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy J Urol 169 2003 136 140
26. G. Trottier, M.J. Roobol, and N. Lawrentschuk Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort BJU Int 108 2011 E237 E244
27. E.W. Steyerberg Clinical prediction models: a practical approach to development, validation, and updating 2009 Springer New York, NY
28. D.G. Altman, and J.M. Bland Missing data BMJ 334 2007 424
29. I.M. Thompson, D.P. Ankerst, and C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 2005 66 70
30. P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, H. Li, and G.L. Lu-Yao Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335 1341
31. T.J. Daskivich, K. Chamie, and L. Kwan Comorbidity and competing risks for mortality in men with prostate cancer Cancer 117 2011 4642 4650